Copyright © 2010 IUPHAR
Annotated and expert reviewed. Please contact us if you can help with updates.
A3
Structural Information  |
|
class A G protein-coupled receptor |
| Species |
TM |
AA |
Chromosomal Location |
Gene Name |
Reference |
| Human |
7 |
318 |
1p13.2 |
ADORA3
|
33,153-155 |
| Rat |
7 |
320 |
2q34 |
Adora3
|
152 |
| Mouse |
7 |
319 |
3 F2.3 |
Adora3
|
156 |
|
|
Database Links  |
|
ChEMBL Target |
280 (Hs), 12171 (Rn) |
|
Ensembl |
ENSG00000121933 (Hs), ENSMUSG00000000562 (Mm), ENSMUSG00000074344 (Mm), ENSRNOG00000015788 (Rn) |
|
Entrez Gene |
140 (Hs), 11542 (Mm), 25370 (Rn) |
|
GeneCards |
ADORA3 (Hs) |
|
HomoloGene |
550 (Hs) |
|
OMIM |
600445 (Hs) |
|
PharmGKB Gene |
PA24589 (Hs) |
|
Protein Ontology (PRO) |
PRO:000001578 (Hs) |
|
RefSeq Nucleotide |
NM_000677 (Hs), NM_009631 (Mm), NM_012896 (Rn) |
|
RefSeq Protein |
NP_000668 (Hs), NP_033761 (Mm), NP_037028 (Rn) |
|
UniGene Hs. |
281342 (Hs) |
|
UniProt |
P33765 (Hs), Q61618 (Mm), P28647 (Rn) |
|
Wikipedia |
A3 |
| Search for 3D structures on the PDB |
|
Search using keywords: Adenosine receptors A3
|
Search using accession numbers: P28647 || P33765 || Q61618
|
| Agonists |
|
Key to terms and symbols
|
View all chemical structures |
Click column headers to sort
|
| Ligand |
|
|
|
|
|
adenosine
|
|
|
|
|
? |
Agonist |
- |
- |
9,188 |
|
[125I]AB-MECA
|
|
|
|
|
Hs |
Full agonist |
9.1 |
pKd |
82 |
|
[3H]AB-MECA
|
|
|
|
|
Hs |
Full agonist |
9.0 |
pKd |
80 |
|
[3H]AB-MECA
|
|
|
|
|
Rn |
Full agonist |
8.9 |
pKd |
179 |
|
[3H]NECA
|
|
|
|
|
Hs |
Full agonist |
7.9 – 8.2 |
pKd |
76,84 |
|
[3H]APNEA
|
|
|
|
|
Hs |
Full agonist |
7.8 |
pKd |
152 |
|
(R,S)-PHPNECA
|
|
|
|
|
Hs |
Full agonist |
9.4 |
pKi |
70 |
|
IB-MECA
|
|
|
|
|
Hs |
Full agonist |
9.2 |
pKi |
76 |
|
IB-MECA
|
|
|
|
|
Hs |
Full agonist |
8.7 – 8.9 |
pKi |
76,82,84 |
|
2-hexynyl-NECA
|
|
|
|
|
Hs |
Full agonist |
8.6 |
pKi |
70 |
|
Cl-IB-MECA
|
|
|
|
|
Hs |
Full agonist |
8.0 – 8.9 |
pKi |
171,180 |
|
PENECA
|
|
|
|
|
Hs |
Full agonist |
8.2 |
pKi |
70 |
|
I-ABA
|
|
|
|
|
Hs |
Full agonist |
8.0 |
pKi |
33 |
|
MRE 3008F20
|
|
|
|
|
Hs |
Full agonist |
8.0 |
pKi |
82 |
|
NECA
|
|
|
|
|
Hs |
Full agonist |
7.5 – 8.4 |
pKi |
33,73,82,107,180 |
|
AB-MECA
|
|
|
|
|
Hs |
Full agonist |
7.7 |
pKi |
76,82 |
|
(R)-PIA
|
|
|
|
|
Hs |
Full agonist |
7.1 – 8.1 |
pKi |
33,73,76,82,180 |
|
CCPA
|
|
|
|
|
Hs |
Full agonist |
7.4 |
pKi |
76 |
|
cyclopentyladenosine
|
|
|
|
|
Hs |
Full agonist |
7.0 – 7.4 |
pKi |
33,73,76 |
|
(S)-PIA
|
|
|
|
|
Hs |
Full agonist |
6.3 – 7.4 |
pKi |
33,76,82 |
|
MPC-MECA
|
|
|
|
|
Hs |
Full agonist |
6.8 |
pKi |
82 |
|
CGS 21680
|
|
|
|
|
Hs |
Full agonist |
6.0 – 7.2 |
pKi |
73,76,82,107 |
|
NECA
|
|
|
|
|
Rn |
Full agonist |
6.6 |
pKi |
179 |
|
(R)-PIA
|
|
|
|
|
Rn |
Full agonist |
6.6 |
pKi |
179 |
|
| View species-specific agonist tables |
| Antagonists |
|
Key to terms and symbols
|
View all chemical structures |
Click column headers to sort
|
| Ligand |
|
|
|
|
|
[3H]MRE 3008F20
|
|
|
|
|
Hs |
Antagonist |
9.1 |
pKd |
82,186 |
|
MRE 3010F20
|
|
|
|
|
Hs |
Antagonist |
9.3 |
pKi |
82 |
|
MRE 3008F20
|
|
|
|
|
Hs |
Antagonist |
9.0 – 9.5 |
pKi |
79,82 |
|
MRS1220
|
|
|
|
|
Hs |
Antagonist |
9.2 |
pKi |
180,182 |
|
MRS1177
|
|
|
|
|
Hs |
Antagonist |
8.5 |
pKi |
182 |
|
MRS1186
|
|
|
|
|
Hs |
Antagonist |
8.1 |
pKi |
182 |
|
MRS1505
|
|
|
|
|
Hs |
Antagonist |
8.1 |
pKi |
184 |
|
VUF8504
|
|
|
|
|
Hs |
Antagonist |
7.8 |
pKi |
185 |
|
I-ABOPX
|
|
|
|
|
Hs |
Antagonist |
7.7 |
pKi |
33 |
|
MRS1476
|
|
|
|
|
Hs |
Antagonist |
7.7 |
pKi |
184 |
|
MRS1523
|
|
|
|
|
Hs |
Antagonist |
7.7 |
pKi |
184 |
|
XAC
|
|
|
|
|
Rn |
Antagonist |
7.7 |
pKi |
179 |
|
DPCPX
|
|
|
|
|
Rn |
Antagonist |
7.6 |
pKi |
179 |
|
MRS1191
|
|
|
|
|
Hs |
Antagonist |
7.5 |
pKi |
180,183 |
|
MRS1486
|
|
|
|
|
Hs |
Antagonist |
7.5 |
pKi |
184 |
|
CGS 15943
|
|
|
|
|
Hs |
Antagonist |
7.0 – 7.9 |
pKi |
76,80,82,182 |
|
BW-A1433
|
|
|
|
|
Rn |
Antagonist |
7.4 |
pKi |
179 |
|
BW-A1433
|
|
|
|
|
Hs |
Antagonist |
7.3 |
pKi |
33 |
|
XAC
|
|
|
|
|
Hs |
Antagonist |
7.0 – 7.4 |
pKi |
33,76,82 |
|
MRS1097
|
|
|
|
|
Hs |
Antagonist |
7.0 |
pKi |
180-181 |
|
MRS1523
|
|
|
|
|
Hs |
Antagonist |
7.0 |
pKi |
184 |
|
VUF8507
|
|
|
|
|
Hs |
Antagonist |
6.7 |
pKi |
185 |
|
MRS1042
|
|
|
|
|
Hs |
Antagonist |
6.5 |
pKi |
83 |
|
MRS1041
|
|
|
|
|
Hs |
Antagonist |
6.4 |
pKi |
83 |
|
MRS1067
|
|
|
|
|
Hs |
Antagonist |
6.2 |
pKi |
83,180 |
|
MRS1088
|
|
|
|
|
Hs |
Antagonist |
6.1 |
pKi |
83 |
|
MRS1093
|
|
|
|
|
Hs |
Antagonist |
6.1 |
pKi |
83 |
|
MRS928
|
|
|
|
|
Hs |
Antagonist |
5.9 |
pKi |
83 |
|
MRS1191
|
|
|
|
|
Rn |
Antagonist |
5.8 |
pKi |
184 |
|
DPCPX
|
|
|
|
|
Hs |
Antagonist |
5.4 – 6.1 |
pKi |
33,76,82 |
|
(R)-niguldipine
|
|
|
|
|
Hs |
Antagonist |
5.7 |
pKi |
181 |
|
galangin
|
|
|
|
|
Hs |
Antagonist |
5.5 |
pKi |
83 |
|
nicardipine
|
|
|
|
|
Hs |
Antagonist |
5.5 |
pKi |
181 |
|
sakuranetin
|
|
|
|
|
Hs |
Antagonist |
5.5 |
pKi |
83 |
|
flavone
|
|
|
|
|
Hs |
Antagonist |
4.8 |
pKi |
83 |
|
flavanone
|
|
|
|
|
Hs |
Antagonist |
4.3 |
pKi |
83 |
|
visnagin
|
|
|
|
|
Hs |
Antagonist |
4.2 |
pKi |
83 |
|
theophylline
|
|
|
|
|
Hs |
Antagonist |
4.1 |
pKi |
76 |
|
|
View species-specific antagonist tables
|
Primary Transduction Mechanisms
|
| Transducer |
Effector/Response |
|
Gi/Go family |
Adenylate cyclase inhibition |
Secondary Transduction Mechanisms  |
| Transducer |
Effector/Response |
|
Gi/Go family |
Phospholipase C stimulation |
Tissue Distribution
|
| Liver, lung > brain, aorta. |
| Species: |
Human |
| Technique: |
Northern blotting. |
| References: |
33 |
|
|
| CNS: corpus callosum, substantia nigra, thalamus, subthalamic nucleus, spinal cord, hippocampus. |
| Species: |
Human |
| Technique: |
Northern blotting. |
| References: |
155 |
|
|
| Adrenal cortex, adrenal medulla > spleen, small intestine. |
| Species: |
Human |
| Technique: |
Northern blotting. |
| References: |
155 |
|
|
| Testes: spermatocytes, round spermatids, elongating spermatids > Leydig cells. |
| Species: |
Rat |
| Technique: |
in situ hybridisation. |
| References: |
36 |
|
|
| Jejunum, ileum, colon. |
| Species: |
Human |
| Technique: |
RT-PCR. |
| References: |
40 |
|
|
| Lung mast cells. |
| Species: |
Mouse |
| Technique: |
RT-PCR. |
| References: |
158 |
|
|
| Brain: hippocampus. |
| Species: |
Rat |
| Technique: |
Western blotting. |
| References: |
173 |
|
|
| Lung, liver, kidney, heart. |
| Species: |
Human |
| Technique: |
Northern blotting. |
| References: |
153 |
|
|
| Liver, lung, placenta. |
| Species: |
Human |
| Technique: |
Northern blotting. |
| References: |
154 |
|
|
Functional Assays
|
| Measurement of IP3 levels in HEK 293 cells transfected with the human A3 receptor. |
| Species: |
Human |
| Tissue: |
HEK 293 cells. |
| Response measured: |
PTX-sensitive increase in IP3 level. |
| References: |
138 |
|
|
| Measurement of cAMP levels in CHO cells transfected with the human A3 receptor. |
| Species: |
Human |
| Tissue: |
CHO cells. |
| Response measured: |
Inhibition of cAMP accumulation. |
| References: |
33 |
|
|
| Measurement of cAMP levels in COS cells transfected with the rat A3 receptor. |
| Species: |
Rat |
| Tissue: |
COS cells. |
| Response measured: |
PTX-sensitive inhibition of cAMP accumulation. |
| References: |
152 |
|
|
| Measurement of extracellular-regulated kinase 1/2 (ERK1/2) phosphorylation in CHO cells transfected with the human A1 receptor. |
| Species: |
Human |
| Tissue: |
CHO cells. |
| Response measured: |
Phosphorylation of ERK1/2. |
| References: |
31,170 |
|
|
| Measurement of cAMP levels and p42/p44 MAPK phosphorylation in a murine dendritic cell line, XS-106, which endogenously expresses A3 receptors. |
| Species: |
Mouse |
| Tissue: |
XS-106 cells. |
| Response measured: |
Inhibition of cAMP and stimulation of p42/p44 MAPK phosphorylation. |
| References: |
108 |
|
|
| Measurement of PKB activity in cardiomyocytes endogenously expressing the A3 receptor. |
| Species: |
Rat |
| Tissue: |
Cardiomyocytes. |
| Response measured: |
PKB phosphorylation via Gi/o. |
| References: |
32 |
|
|
| Cell number count of CHO cells transfected with the human A3 receptor. |
| Species: |
Human |
| Tissue: |
CHO cells. |
| Response measured: |
Reduction of cell number. |
| References: |
171 |
|
|
| Measurement of eosinophil peroxidase and superoxide anion release from human eosinophils endogenously expressing the human A3 receptor. |
| Species: |
Human |
| Tissue: |
Eosinophils. |
| Response measured: |
Release of of eosinophil peroxidase and superoxide anion . |
| References: |
172 |
|
|
Physiological Functions
|
| Mast cell activation. |
| Species: |
Mouse |
| Tissue: |
Lung mast cells. |
| References: |
158 |
|
|
| Inhibition of noradrenaline release from peripheral sympathetic nerve terminals. |
| Species: |
Rat |
| Tissue: |
Mesenteric artery. |
| References: |
128 |
|
|
| Preconditioning. |
| Species: |
Rat |
| Tissue: |
Heart. |
| References: |
174 |
|
|
| Coronary vasodilation. |
| Species: |
Rat |
| Tissue: |
Heart. |
| References: |
147 |
|
|
| Protection from reperfusion/reoxygenation injury. |
| Species: |
Rat |
| Tissue: |
Heart. |
| References: |
129 |
|
|
| Localised inflammatory response in peripheral tissues. |
| Species: |
Mouse |
| Tissue: |
In vivo (hind paw). |
| References: |
162 |
|
|
| Regulation of intraocular pressure. |
| Species: |
Mouse |
| Tissue: |
In vivo (eye). |
| References: |
163 |
|
|
| Preconditioning. |
| Species: |
Mouse |
| Tissue: |
Heart. |
| References: |
175 |
|
|
| Modulation of synaptic plasticity. |
| Species: |
Rat |
| Tissue: |
Hippocampus. |
| References: |
176 |
|
|
| Modulation of ischemia/reperfusion injury. |
| Species: |
Mouse |
| Tissue: |
In vivo. |
| References: |
165-166 |
|
|
| Hypotension. |
| Species: |
Rat |
| Tissue: |
In vivo. |
| References: |
177 |
|
|
| Mast cell degranulation. |
| Species: |
Rat |
| Tissue: |
Mast cells. |
| References: |
178 |
|
|
Physiological Consequences of Altering Gene Expression
|
| A3 knockout mice exhibit no potentiation of antigen-dependent degranulation of bone marrow-derived mast cells, as with the wild-type mice, and decreased inhibition of TNFα production. |
| Species: |
Mouse |
| Tissue: |
|
| Technique: |
Gene targeting in embryonic stem cells. |
| References: |
159 |
|
|
| A3 receptor knockout mice exhibit decreased adenosine-induced airway responsiveness. |
| Species: |
Mouse |
| Tissue: |
|
| Technique: |
Gene targeting in embryonic stem cells. |
| References: |
160 |
|
|
| A3 receptor knockout mice exhibit protection from ischemic or myoglobinuric renal failure. |
| Species: |
Mouse |
| Tissue: |
|
| Technique: |
Gene targeting in embryonic stem cells. |
| References: |
161 |
|
|
| A3 receptor knockout mice exhibit defective localised inflammatory responses. |
| Species: |
Mouse |
| Tissue: |
|
| Technique: |
Gene targeting in embryonic stem cells. |
| References: |
162 |
|
|
| A3 receptor knockout mice exhibit reduced intraocular pressure. |
| Species: |
Mouse |
| Tissue: |
|
| Technique: |
Gene targeting in embryonic stem cells. |
| References: |
163 |
|
|
| Overexpression of the A3 receptor gene by the SM22 alpha promoter resulted in lethality at an early stage of embryo development. |
| Species: |
Mouse |
| Tissue: |
|
| Technique: |
Transgenesis. |
| References: |
164 |
|
|
| A3 receptor knockout mice exhibit resistance to cardiac ischemia-reperfusion injury. |
| Species: |
Mouse |
| Tissue: |
|
| Technique: |
Gene targeting in embryonic stem cells. |
| References: |
165-166 |
|
|
| A3 receptor knockout mice exhibit increased cAMP levels in the heart and vascular smooth muscle, as well as a decrease in blood pressure. |
| Species: |
Mouse |
| Tissue: |
|
| Technique: |
Gene targeting in embryonic stem cells. |
| References: |
167 |
|
|
| A3 receptor knockout mice exhibit defective cutaneous vascular permeability. |
| Species: |
Mouse |
| Tissue: |
|
| Technique: |
Gene targeting in embryonic stem cells. |
| References: |
168 |
|
|
| A3 receptor knockout mice exhibit great carbon monoxide-induced neuronal damage, slightly increased locomotor activity and altered response to painful stimuli. |
| Species: |
Mouse |
| Tissue: |
|
| Technique: |
Gene targeting in embryonic stem cells. |
| References: |
169 |
|
|
|
Receptor Comments |
|
For a review of the effects of adenosine receptor knockout on nervous system function see reference [9]. |
To cite this receptor data page, please use the following:
Bertil B. Fredholm, Bruno G. Frenguelli, Rebecca Hills, Adriaan P. Ijzerman, Kenneth A. Jacobson, Joel Linden, Ulrich Schwabe, Gary L. Stiles.
Adenosine receptors: A3. Last modified on 2010-08-24. Accessed on 2010-09-03. IUPHAR database (IUPHAR-DB), http://www.iuphar-db.org/DATABASE/ObjectDisplayForward?objectId=21.
Contact us | Print | Back to top | Help